Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Mult Scler ; 17(7): 851-66, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21561957

RESUMEN

BACKGROUND: In multiple sclerosis inflammation is primarily injurious to the central nervous system, but its therapeutic suppression might inhibit repair-promoting factors. OBJECTIVES: We aimed at better describing the complexity of biological effects during an acute relapse and analysed the effects of intervention with high-dose i.v. glucocorticoids and immunomodulatory treatment with interferon-beta (IFNß). METHODS: We studied the intracellular expression levels of the pro-inflammatory mediators tumour necrosis factor alpha (TNFα) and inducible nitric oxide synthase (iNOS) together with the neurotrophins ciliary neurotrophic factor (CNTF) and brain-derived neurotrophic factor (BDNF) in freshly isolated peripheral blood mononuclear cells of multiple sclerosis patients during an acute relapse, after intervention with i.v. methylprednisolone and at baseline, using a highly quantitative flow-cytometric approach. RESULTS: We demonstrated the expression of CNTF in human leucocytes. We showed that CNTF levels differed in acutely relapsing multiple sclerosis patients compared with controls and increased after corticosteroid treatment. CNTF can counteract the toxicity of TNFα towards oligodendrocytes and we found TNFα increased during acute relapses. Following corticosteroids, neither TNFα nor iNOS expression was reduced. Levels of BDNF were not affected by glucocorticoids, but increased during IFNß therapy. However, IFNß also increased the expression of iNOS and major histocompatibility complex class I (MHC-I), underlining its immunomodulatory potential. CONCLUSIONS: Multiple sclerosis patients might benefit from reparative, and not solely from anti-inflammatory, effects of glucocorticoids. Interactive effects of glucocorticoid- and IFNß-treatment need to be considered to improve neuroprotection and remyelination resulting from immunomodulatory treatment.


Asunto(s)
Glucocorticoides/administración & dosificación , Factores Inmunológicos/uso terapéutico , Mediadores de Inflamación/sangre , Interferón beta/uso terapéutico , Leucocitos Mononucleares/efectos de los fármacos , Metilprednisolona/administración & dosificación , Esclerosis Múltiple Crónica Progresiva/tratamiento farmacológico , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Factores de Crecimiento Nervioso/sangre , Adulto , Factor Neurotrófico Derivado del Encéfalo/sangre , Estudios de Casos y Controles , Separación Celular/métodos , Células Cultivadas , Factor Neurotrófico Ciliar/sangre , Quimioterapia Combinada , Femenino , Citometría de Flujo , Humanos , Interferón beta-1a , Interferon beta-1b , Leucocitos Mononucleares/inmunología , Leucocitos Mononucleares/metabolismo , Masculino , Persona de Mediana Edad , Esclerosis Múltiple Crónica Progresiva/sangre , Esclerosis Múltiple Crónica Progresiva/diagnóstico , Esclerosis Múltiple Crónica Progresiva/inmunología , Esclerosis Múltiple Recurrente-Remitente/sangre , Esclerosis Múltiple Recurrente-Remitente/diagnóstico , Esclerosis Múltiple Recurrente-Remitente/inmunología , Óxido Nítrico Sintasa de Tipo II/sangre , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/sangre , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA